REGN vs URGN: which is the better buy in 2026?
On Alexandria's Compass, UroGen Pharma Ltd. has the edge with a 90/100 score versus 88/100 for REGN. Here is how they stack up, factor by factor.
Regeneron Pharmaceuticals
NASDAQ:REGN
Dupixent's global dominance and a deep late-stage pipeline make REGN a rare large-cap biotech trading below its growth rate.
Full REGN analysisUroGen Pharma Ltd.
NASDAQ:URGN
Zusduri is rewriting how urologists treat bladder cancer, and the early script data is louder than the share price suggests.
Full URGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is REGN or URGN the better buy in 2026?
By Compass Score, UroGen Pharma Ltd. (NASDAQ:URGN) edges it at 90/100 versus 88/100 for REGN. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare REGN and URGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.